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Specific recognition of antigen by thymus-derived (T) effector cells in delayed
hypersensitivity response (DHR)' in vivo (1), and cell-mediated cytotoxicity in
vitro (2-4), implies_ that these cells have specific receptors for antigen. Cytotoxic
T cells can adhere specifically to allogeneic (2) and xenogeneic (4) target cell
monolayers ; and both precursor and effector T cells in delayed hypersensitivity
can be specifically inactivated with ...I-labeled antigen (1) .
The specific adherence of sheep erythrocytes (SRBC) to lymphocytes to form
rosettes is a useful technique to study the function of SRBC-specific T and bone
marrow-derived (B) rosette-formingcells (RFC). TRFC bind fewerSRBCthan B
RFC (5-8) and tend to dissociate after resuspension of the pellet (9) . If a
metabolic inhibitor, sodium azide, is added immediately after resuspension of
the pellet, viable T rosettes can be stabilized and purified for functional studies
(10). Previous work has shown that small lymphocyte T RFC are neither helper
cells in the antibody response nor effector cells inthe DHR against SRBC (10). In
the present investigation, effector cells in DHR and in vitro cytotoxicity
correlated with non-RFC small T lymphocytes and with medium lymphoid T
RFC.
Materials and Methods
Animals.
￿
Male C57BL/6 mice (Canadian Breeding Laboratories, Montreal, Quebec) 6-8 wk of
age were used.
Medium.
￿
Tris (hydroxymethyl)-amino-methane-buffered (pH 7.4) Eagle's minimal essential
medium (MEM) (Grand Island Biological Co ., Grand Island, N. Y.) was used for preparing cells.
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CMRL 1066 (GIBCO) supplemented with 10% fetal calf serum, glutamine, nonessential amino acids,
and pyruvate was used for tissue culture. The pH was adjusted to 7.4 with a bicarbonate buffer. All
cultures were incubated in a humidified incubator gased with 5% CO, in air.
Antigens andImmunization.
￿
Sheep or donkey blood wascollected and stored in an equal volume
of Alsever's solution. Allogeneic CBA mouse erythrocytes (MRBC) were obtained by bleeding from
the neck into Alsever's solution immediately after cervical dislocation andwere used on the same day.
Immunization was by the intradermal injection of5 x 10' erythrocytes emulsified (1:1 by volume)
in complete Freund's adjuvant (Difco Laboratories, Detroit, Mich .). A vol of 0.05 ml was injected
intradermally into the right foot pad of each mouse. In some experiments keyhole limpet hemocyanin
(KLH) (Schwarz/Mann Div., Becton, Dickinson & Co., New York), emulsified with adjuvant, was
used as antigen (1.25 ug KLH/mouse) .
Sodium Azide and Neuraminidase Treatment .
￿
Sodium azide (Fisher Scientific Co., Pittsburgh,
Pa.) andneuraminidase were used as previously described (10) . Treatment with 0.05% azide, followed
by washing in medium without azide, had no effect on the activity of effector cells.
Ammonium Chloride Treatment.
￿
In some experiments erythrocytes were removed from fraction-
ated cell suspensions by NH,Cl lysis (11) before testing for effector cell activity. Treatment with
NH,CI had no effect on the activity of effector cells.
Preparation of Cell Suspension and Formation of Rosettes.
￿
Cells from spleen or axillary and
popliteal lymph nodes were teased into MEM. Single cell suspensions were prepared and rosettes
against SRBC were made as previously described (10) .
Velocity Sedimentation .
￿
The technique of velocity sedimentation at unit gravity (12) wasused to
separate single cells and rosettes by differences in size (9, 10). Nucleated cells (8 x 10') plus 8 x 10'
SRBC were loaded into each of twosedimentation chambers, andwere sedimented for 1.5 h. Common
fractions were pooled as indicated below. In some experiments, sodium azide wasadded to the rosette
suspension and sedimentation medium to a final concentration of 0.05%.
Lymphocytes were categorized by diameter as defined by Metcalf and Wiadrowski (13). Small
lymphocytes (G7 /+m) sedimented at 3-4 mm/h, medium (7-11 um) at 5-7 mm/h, and large (>11
um) at greater than 8 mm/h (9) .
Equilibrium Density Gradient Centrifugation.
￿
Equilibrium density gradient centrifugation (14)
was used to separate cells by buoyant density. A continuous density gradient of bovine serum
albumin ranging from 1.045-1 .075 g/cm' was used . The gradient was spun at 4°C, at 3,800 g for 45
min. After centrifugation, 15 drop fractions were collected and the mean density of each fraction was
determined by measuring the refractive index. Fractions were washed in tissue culture medium,
counted, and tested for functional properties as described below.
Assay for Foot Pad Swelling.
￿
DHR was assayed by measuring the percent increase in foot pad
volume after skin testing with antigen. Foot pad volume was proportional to the deflection observed
on a Mettler 1600 balance (Fisher Scientific Co.) when the mouse foot was immersed in mercury to a
mark made immediately distal to the lateral malleolus (15). Three readings were made on each foot
and then averaged. The difference in readings before and after skin testing was proportional to the
increase in foot pad volume. The percent increase in foot pad volume was calculated by dividing the
difference by the original reading and multiplying by 100%.
Adoptive Transfer of DHR.
￿
A system was developed to transfer delayed hypersensitivity into
normal syngeneic mice. Immune cells were intradermally injected with 5 x 10' SRBC (in 0.02 ml with
a no. 27 needle) into the right foot pad of five mice per group. The other foot pad was injected with
antigen alone as a control. Thepercent increase in foot pad volume was determined. In experiments
involving cell separation, all the cells of each fraction were transferred with SRBC . The relative
effector cell activity of immune cells was determined from the dose response graph in Fig. 2 andwas
expressed as the relative number of effector cells injected per mouse.
Assay for In Vitro Cytotoxicity.
￿
An in vitro microcytotoxicity assay similar to the method of
Takasugi and Klein (16) was developed to test for cytotoxic cells directed against sheep fibroblasts
which bear serologically detectable SRBC antigens (B. E. Elliott, unpublished results) . Sheep
fibroblasts were grown from a sterile biopsy of sheep skin (1 mm x 1 cm). After removing the outer
layer, the skin wascutinto small pieces with a scalpel blade and incubated in culture dishes (60 mm
in diameter, no. 3002, Falcon Plastics, Div. of BioQuest, Oxnard, Calif.), for 6-7 days. On the dayof
an experiment, the supernate was removed; the remaining monolayer of adherent fibroblasts was
incubated at 37°C for 20 min with 0.025% trypsin in phosphate-buffered saline. Cells were then586
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washed in tissue culture medium, counted in 1% eosin yellow stain (Fisher Scientific Co.), and
adjusted to 3 x 108 viable cells/ml. One drop (0.03 ml from a Pasteur pipette) of tissue culture
medium and one drop of the fibroblast suspension were added to each well of a microtitration tray
(Microtest Tissue II Culture Dishes, no. 3040, Falcon Plastics) to yield 100viable fibroblasts per well.
In some experiments, human melanoma tumor cells or rat fibroblasts were harvested from cultured
cell lines and used as target cells.
Viable cells to be tested in the microcytotoxicity assay were adjusted to the required concentration
and one drop of the cell suspension was added to each of five wells per group . Controls consisted of
wells with fibroblasts alone.
Cytotoxicity wasscored at 20 h or as indicated below. Two drops of 1% eosin in normal saline were
added to each well. Nonadhering cells were removed by one gentle aspiration with aPasteur pipette.
Adhering viable fibroblasts (i.e., cells excluding the dye [171) were counted with an Olympus inverted
microscope (Olympus Corporation of America, New Hyde Park, N. Y.). The number of adhering
target cells per control well varied between experiments, but was constant within an experiment.
Thepercent inhibition offibroblasts wasdetermined by the following formula: %Inhibition = [1 -
(x - y) 1 x 100%; where x is the average number of viable fibroblasts per well with lymph node cells,
and y is the average number of viable fibroblasts in the control wells without lymph node cells. The
relative effector cell activity after treatment of immune cells was the number of untreated cells per
target cell (interpolated from the dose response curve in Fig. 3) required to yield the same percent
fibroblast inhibition as treated cells .
In experiments involving velocity sedimentation, each cell fraction was cultured at a ratio of
immune cells to target cells of250:1, except for fractions in the highvelocity regions (E, F, andG; Fig.
5) which were cultured at a ratio of 50:1 . The enrichment of each fraction was calculated by dividing
the relative immune cell activity of each fraction by the activity of an equivalent number of untreated
cells. The relative effector cell number per fraction was the product of the enrichment and the total
number of cells per fraction.
Trypsinization. Cells were washed in phosphate-buffered saline, and incubated with 0.025%
trypsin (Sigma Chemical Co., St . Louis, Mo.) in phosphate-buffered saline. After incubation at 37°C,
the cells were washed twice in MEM.
Treatment with Antisera.
￿
In all experiments a two-step procedure was used. Antiserum at the
required dilution in phosphate-buffered saline was added to the pellet of cells to yield a final cell
concentration of 5 x 10'/ml. Cells were incubated at 25°C. After 30 min complement (C) was added
to a final dilution of 1/8. The cells were then incubated at 37°C for 45 min. Controls consisted of cells
incubated alone, or with antiserum ( 1/,o), or with C. After the final incubation, cells were washed in
1066; viable cells were counted with 1% eosin stain andfunctional tests were performed, as described
below.
AKR anti-C3HB serum (a gift from Dr. R. S. Kerbel, Queens University, Kingston, Ontario) and
goat antimouse immunoglobulin (anti-1g) serum (Melloy) were used with guinea pig serum (GPS) at a
final dilution of 1/8. Anti-Ly-4.2 serum (a gift from I. McKenzie, University of Melbourne, Melbourne,
Australia) was used with normal rabbit serum (1/8) as a source of C. This alloantiserum is specific
for Bcells (I. McKenzie, personal communication). Rabbit serum wasabsorbed with C57BL/6thymus
and spleen cells (1 volume of cells to 7 volumes of serum).
Assay for Cross-Reactivity of Antibody .
￿
Anti-SRBC antibody was obtained from hyperimmune
mice and the hemagglutination titer (18) against SRBC, donkey erythrocytes (DRBC), or MRBC was
determined. Cross-reactivity with SRBC wascalculated by dividing the titer ofeach erythrocyte with
that of SRBC, and multiplying by 100%.
Assay for Cross-Reactivity in the Production of Plaque-Forming Cells (PFC) .
￿
SRBC-immune
lymph node cells were cultured with 1 x 10' SRBC or DRBC were assayed 4 days later by the
technique of Cunningham and Szenberg (20) . Cross-reactivity was determined by dividing the
number of anti-SRBC PFC in cultures with DRBC, by the number of anti-SRBC PFC in cultures
with SRBC, and multiplying by 100%. Since there is very little cross-reactivity at the antibody level
with these antigens (Table I), themajority of cross-reactivity observed is thought to be at the level of
helper T cells (21).
Results
Kinetics of Induction of DHR.
￿
Mice were immunized with SRBC, with or
without adjuvant, in one foot pad. At various times, the other foot pad was skintested, and thepercent increase in foot padvolume was measured 20h later. The
maximum foot pad swelling occurred when immune mice were challenged 9 days
after immunization (Fig. 1). Immunization with a low antigen dose, or without
adjuvant, resulted in a much smaller reaction . Both mononuclear and polynu-
clear cells infiltrated into the foot pad of immune animals after skin testing with
antigen as reported by other investigators (1). Normal animals skin tested with
SRBC gave noreaction . The subsequent experiments were designed to character-
ize the DHR and cytotoxicity reaction which were maximal at 9 days after
immunization.
Dose Response Relationship . The effect of the dose of immune cells on
effector cell activity was determined for both DHR and in vitro cytotoxicity.
For DHR, doses of 5 x 10`-1 x 108 SRBC-immune lymph node cells were
transferred intradermally with antigen: the percent increase in foot pad volume
(measured after 18 h) was proportional to the immune cell dose. SRBC alone,
immune cells alone, or nonimmune cells plus SRBC produced no swelling (Fig.
2).
For cytotoxicity, immune cells were cultured at ratios of lymph node cells to
target cells ranging from 50:1 to 1,000:1. Cytotoxicity against sheep fibroblasts
was directly proportional to the number ofimmune cells at ratios ofimmune to
target cells between 50:1 and 800:1 (Fig. 3). No cytotoxicity was observed when
normal lymph node cells were cultured with sheep fibroblasts, or when
SRBC-immune lymph node cells were cultured with human melanoma cells or
with rat fibroblasts (unpublished result). These data suggest that the cytotoxic
cells act specifically against sheep fibroblasts, and that background target cell
killing is minimal.
Effect of Antisera on Effector Cell Activity.
￿
SRBC-immune lymph node cells
(2.5 x 10'/group) were treated with different dilutions of anti-B serum or anti-Ig
serum, plus C, and were tested for DHR or in vitro cytotoxicity. Foot pad
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Kinetics of induction of DHR. Mice immunized with 5 x 10' SRBC in CFA, 1 x 10'
SRBC in CFA, or 5 x 10' SRBC alone, were challenged with 5 x 10' SRBC at various times
after immunization. Foot pad volumes were measured 18 h after challenge. A control con-
sisted of untreatedanimals.588
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Effect of immune cell dose on foot pad swelling. Doses of immune lymph node cells
from 9-day immune mice were injected intradermally with 5 x 10' SRBC into one foot pad.
Controls consisted of the other foot pad injected with SRBC alone. Each point represents the
mean increase in foot pad volume (after 18 h) of five animals t the standard error.
volumes were measured 18 h after foot pad challenge and microcytotoxicity was
scored after 36 h of culture with target cells.
Greater than 90% of the effector cell activity was lost after treatment with
anti-9 serum ('/,o) plus GPS (Table I) . No activity was lost after incubation with
GPS or anti-B serum alone. Similar results were obtained with two anti-9 sera,
supplied by I. McKenzie and R. S. Kerbel. In contrast, treatment with anti-Ig
serum (dilution 1/a) plus C or with anti-Ly-4.2 serum plus rabbit C, did not
inhibit effector cell activity, although specific killing of immune lymph node cells
was observed (Table 1) .
Size and Rosette-Forming Ability of Effector Cells.
￿
Without prior rosette
formation, DHR effector cells (assayed 18 h after foot pad challenge) sedimented
as small and medium lymphocytes (fractions A, B, and C; Fig. 4 B) .
When immune cells were subjected to rosette formation before sedimenting
with azide, both T- and B-type rosettes sedimented at velocities greater than 6.5
mm/h (Fig. 4 A) . Fractions E and F contained medium lymphocyte T-type
rosettes. Fraction G contained multilayered rosettes, previously shown to be
antibody secreting cells (9). Significant DHR activity remained in the nonrosette
small lymphocyte fraction; but the medium lymphocyte effector cells sedimented
as rosettes into fractions E and F. No DHR activity was associated with fraction
G. Without azide to stabilize T rosettes, the medium lymphocyte rosettes
dissociated and all effector cells sedimented as single cells in the small and
medium lymphocyte regions (Fig . 4 B) .
Cytotoxic effector cells displayed similar sedimentation properties . When the
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Effect of immune cell dose on in vitro cytotoxicity. Lymph node cells from 9-day im-
mune animals were cultured at different immune cell to target cell ratios in the wells of a
microtitration tray. Controls consisted of immune cells cultured with human melanoma tumor
cells and normal lymph node cells cultured with sheep fibroblasts. Each point represents the
mean percent fibroblast inhibition (after 20 h) t the standard error.
percent fibroblast inhibition was scored at 20 h, cytotoxicity was associated only
with medium lymphocytes (fractions B and C; Fig. 5 A); after rosette formation
these cells sedimented as rosettes in fractions E and F. At 36 h, cytotoxicity was
associated with both nonrosette-forming small lymphocytes (fraction A) and
medium lymphocyte rosettes (fractions E and F) (Fig. 5 B) . Without azide to
stabilize T rosettes, effector cells sedimented as single cells (Fig . 5 A) .
Anti-B Treatment of DHR Effector Cells.
￿
After treatment with anti-8 serum
plus C, 90% of the effector cell activity of both the nonrosette-forming small
lymphocytes (fraction A) and the medium lymphocyte RFC (fraction EF) was
lost . Incubation alone, or with sera alone, had no effect on effector cell activity
(Fig. 6) .
Kinetics of Fractionated Effector Cells.
￿
The kinetics of effector cell activity
in DHR and cytotoxicity were compared. Rosettes were made from immune
lymph node cells, stabilized by sodium azide, and separated by velocity
sedimentation . Activity of fractionated effector cells in DHR and in vitro
cytotoxicity was measured at various times after challenge with antigen.
Medium lymphocyte effector RFC produced a maximum foot pad swelling at590
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TABLE I
Effect of Antisera Treatment on DHR and Cytotoxicity
Treatment
Control (37°C)
c' *
B$ (1:20)
c' + 0 (1:20)
c' +0(1:60)
c' + 0 (1:180)
c' +0 (1:540)
Anti-Ig (1:8)
c'* + anti-Ig (1 :8)
anti-Ly-4.2§ (1:10)
c' 11 + anti Ly-4.2 (1 :10)
* c', guinea pig C.
$0, AKR anti-C,HO.
§ (BALB/c x SWRW, anti-B10.D2 (a gift from I. McKenzie).
11 c', rabbit C.
12 h; the maximum swelling produced by the nonrosette-forming small lympho-
cytes occurred at 20 h. Fractions C and D were completely unresponsive. An
equivalent number of unfractionated cells produced a foot pad swelling response
whichwas a composite of the response of both the small and medium lymphocyte
effector cells (Fig. 7 A) . No swelling was observed in the first 4 h. However, when
anti-SRBC serum plus SRBC were injected intradermally there was an immedi-
ate swelling at 4 h which disappeared after 10 h; this immediate reaction was
distinct from the delayed cell-mediated footpad swelling reaction (B . E. Elliott,
unpublished result).
The medium lymphocyte effector RFC (fractions E and F) developed detecta-
ble cytotoxic activity after 15 h of culture with fibroblasts. Nonrosette-forming
small lymphocytes (fraction A) were inactive at 22 h; they developed detectable
cytotoxic activity after 36 hof culture. Fractions C and G produced no activity at
any time (Fig. 7 B).
Comparison of the Buoyant Density of Medium Lymphocyte Effector Cells in
DHR and In Vitro Cytotoxicity . For further comparison of DHR and cytotoxic
effector cells, medium lymphocytes (fraction B and C) were separated from
immune lymph node cells by velocity sedimentation and subjected to equilib-
rium density gradient centrifugation . Nucleated cells were present in both the
light and denseregions of the gradient and were pooled into six density fractions
(Fig . 8). The majority of cells in fractions 1, 2, and 3 were medium lymphocytes
(less dense) ; andthe majority of cells in fractions 5 and 6were small lymphocytes
(more dense) (14) . The latter represent contamination from fraction A of the
sedimentation. The relative DHR and cytotoxic effector cell numbers per fraction
were determined .
HR
Recovered
cells
Survival of
activity
Cytotoxicity
Treatment
Survival of
activity
100 100 Control (37°C) 100
91 80 :1- 10 c' * 83 t 12
90 100 t 8 O$ (1:10) 78 t 8
60 12 f 2 c' + 6 (1:10) 9.5 1 5
56 28 t 12 c' + 0 (1:30) 15 f 5
76 68 t 14 c' + 0 (1:90) 60 t 20
84 100=E 10 c' + 0 (1:270) 83 t 13
100 84 f 13 anti-Ig 95 t 14
44 96 t 11 c' * + anti-Ig 87 t 16
96 NT anti-Ly 4.2 80 t 11
48 NT c' 11 + anti-Ly-4.2 95 t 12W
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Effect of velocity sedimentation on DHReffector cells. (A) Rosettes were made from
immune lymph node cells andsubjected to velocity sedimentation with sodium azide present.
The absolute number of rosettes per fraction and the percent of total nucleated cells per
fraction is shown. (B) Immune cells were subjected to velocity sedimentation (a) without prior
rosette formation, or (b) with rosette formation plus sodium azide, or (c) with rosette forma-
tion but without sodium azide. Each fraction was assayed for DHR and the relative effector
cell number injected per mouse was determined from Fig. 2. Each point was normalized to
representequivalent unitsofsedimentation velocity.
Effector cells in both delayed hypersensitivity and in vitro cytotoxicity were
associated with fractions 2 and 3 (1 .0565-1.0640 g/cm') . A minor peak of DHR
activity in fraction 6 (> 1.070 g/cm9) correlated with the contaminating small
lymphocytes present in that fraction.
Cross-Reactivity of Effector Cells. Cross-reactivity in the induction of592
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Effect ofvelocity sedimentationon cytotoxic effector cell activity . Immune lymphnode
cellswere sedimented as in Fig. 4B. Each fraction wascultured in a microcytotoxicity test with
sheep fibroblasts . (A) The percent fibroblast inhibition was scored after 20 h. FractionsB and
C (without rosette formation) produced 70 and 73% inhibition, respectively . Fractions E and
F (with rosette formation plus azide) produced 78 and 92% inhibition, respectively . The rela-
tive number of effector cells.per fraction was determined . Thedistributions arenormalized to
an arbitrary scale . (B) The percent fibroblast inhibition was scored after 36h .
effector cells was determined by testing lymph node cells immunized against
DRBC, SRBC, MRBC, or KLH, forDHR or cytotoxicity against SRBC or sheep
fibroblasts . Foot pad volumes were measured 18 h after challenge; fibroblast
inhibition was scored after 36 h . Cross-reactivity was calculated by dividing the
relative activity of effector cells immunized with KLH, DRBC, or MRBC, by the
relative activity of the SRBC immune effector cells and multiplying by 100% .
The results in Table III indicate significant cross-reactivity with DRBC, of both
DHR and cytotoxic effector cells; but no cross-reactivity withMRBC or KLH.
The degree of cross-reactivity of these antigens with SRBC in the induction of
effector cells is similar to that observed in helper cell activity in the production of
PFC. Antibody against SRBC cross-reacted much less with DRBC and MRBC
(as determined by a hemagglutination test) (Table II) .
The specificity of erythrocyte binding by effector cells was determined by
subjecting SRBC-immune lymph node cells to rosette formation with MRBCB. E. ELLIOTT, J . S . HASKILL, AND M. A. AXELRAD
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Effect ofanti-6 serum on fractionated effector cells in DHR. Immune cell fractions from
a velocity sedimentation (plus azide) with prior rosette formation were incubated alone, or
with C, or with anti-8 serum plus C. Each group was tested for DHR(in an 18 h assay) andthe
relative number of effector cells wasdetermined.
before sedimenting. Anti-SRBC effector cell activity remained in the small and
medium lymphocyte regions; medium lymphocyte effector RFC did not bind
MRBC . If rosettes from SRBC-immune cells were made against DRBC before
sedimenting, significant effector cell activity was associated with the medium
lymphocyte rosette fraction. This activity represented 25% cross-reactivity with
DRBC of SRBC-immune medium lymphocyte effector cells (unpublished
observations) .
Effect of Trypsinization on the Function of Effector Cells.
￿
The nature of
antigen receptors on rosette-forming effector cells was investigated by treatment
of immune cells with trypsin . After 5 min of trypsinization, less than 10% of the
original number of RFC still formed rosettes (Table III) . These results suggest
that antigen receptors were altered or removed by enzyme treatment . No loss of
DHR or cytotoxic effector cell activity was observed after periods of trypsiniza-
tion ranging from 10 to 40 min . When cells were washed after 10 min of
trypsinization, regeneration of rosette-forming ability was observed within 60
min ; by 180 min, 95% of the original number of T RFC and B RFC had regained
the ability to bind SRBC (Table IV) .
Discussion
Since both T and non-T cells maybe involved in cellular immune reactions (22),
it is important to define clearly the type of Effctor cell detected . In the present
work, 90% of the activity in DHR and cytotoxicity was abolished by anti-8 serum
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Ftc. 7. Kinetics of fractionated effector cells. (A) Fractions were pooled into AB(2-6.5
mm/h), CD (6.5-11 mm/h), and EFG(> Il mm/h). Each fraction was tested for DHR
activity and the relative effector cell number injected per mouse was determined at various
times after culture. (B) Immune lymph node cells were subjected to rosette formation and
sedimented with azide present. Fractionated cells were cultured with sheep fibroblasts, and
the percent fibroblast inhibition was determined at various times after culture. The relative
effector cell number of fractions (A + B), (C + D), and (E + F) was plotted vs, time.
plus C, but was insensitive to anti-Ig serum or anti-Ly-4.2 serum plus C. T cells
aretherefore the main mediators of DHR and cytotoxicity observed; Ig-bearing B
cells were not involved .
The response was antibody independent, since multilayered rosettes secreting
19S and 7S antibody, which sedimented in fraction G (B . E. Elliott, unpublished
result), were inactive in both in vivo and in vitro assays. Furthermore, the
kinetics of the foot pad swelling response after the transfer of immune cells into
normal animals was characteristic of a delayed response in contrast to the 4 h
antibody-mediated response which disappeared after 10 h (Fig . 7 A) . The DHR
response was thus distinct from the immediate Arthus-type reaction (23) .
Activity in DHR and in vitro cytotoxicity was associated with a nonrosette-
forming small lymphocyte and a medium lymphoid T RFC. Activity of both cell
types was sensitive to anti-B serum plus C. The antigen-binding property of the
medium lymphocyte effector cells was characteristic of T RFC. The effector cell
rosette dissociated in suspensions without. azide (Figs. 4 and 5) .
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￿
Comparison of buoyant density of medium lymphocyte effector cells in DHR and in
vitro cytotoxicity. Medium lymphocytes, separated by velocity sedimentation (fractions B and
C), were subjected to equilibrium density gradient centrifugation. Density regions were pooled
into six fractions and each fraction was assayed for delayed hypersensitivity or in vitro
cytotoxicity (the immune cell to target cell ratio was250:1). Foot padswelling (16% in fractions
2 and 3) and percent fibroblast inhibition (76% in fraction 2) were assayed after 18 h, and the
relative number of effector cells per fraction was determined.
TABLE II
Comparison of Cross-Reactivity of T- and B-Cell Functions
T
B
* The mean t the standard error ofat least two experiments is indicated.
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The medium lymphocyte effector RFC sedimented as rosettes are a mean
velocity of 13-15 mm/h (Figs. 4 and 5). The number ofbound SRBC required to
make a medium lymphocyte sediment at this velocity is 7-10. This velocity has
previously been associated with small lymphocyte B rosettes binding an average
of 18 SRBC per RFC (9). However, the medium lymphocyte was larger, and
sedimented at 5-7 mm/h comparedto thesmall lymphocyte which sedimented at
3-4 mm/h (24). Assuming the following mean volumes, SRBC, 32pm3(25); small
Function
Cross-reactivity with
DRBC MRBC
SRBC
KLH
Induction ofcytotoxic cells 55 t 8* 0 0
Effector cells in DHR 28 t 4 0 0
Helper activity in PFC 40+5 NT NT
production
Anti-SRBC antibody 8 1 NT596
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TABLE III
Effect of Trypsinization on Rosette Formation and
Activity Effector Cell
Incubation Treatment
time
￿
(0.025% trypsin)
0
￿
-
￿
100 100 100
* The mean t the standard error of two experiments is indicated.
$ The mean t the standard error of five animals per point is indicated .
TABLE IV
Recovery of T and B RFC after 10 min Trypsinization
Survival ofactivity
RFC* ￿DHR $
￿
Cytotoxicity*
RFC class
lymphocyte, 172 Am' (14) ; medium lymphocyte, 400 am' (14) ; the following
volumes can be calculated, small lymphocyte with 18 SRBC bound, 750jm 3 and
medium lymphocyte with 10 SRBC bound, 720 jm3. Sincethe medium lymphoid
T rosettewith 10 SRBC bound was the same size as the small lymphoid B rosette
(with 18 SRBC), both types of rosettes sedimented at the same velocity (13-15
mm/h). The effector RFC observed therefore, bound an average of 7-10 SRBC,
were sensitive to anti-B serum plus C, and were therefore, T RFC.
The present work is a direct demonstration of a function of medium
lymphocyte T RFC in cell-mediated immunity against SRBC. These results
imply that the medium lymphocyte effector T cells bind SRBC specifically . The
degree of cross-reactivity, between DRBC and SRBC, in the induction of effector
cells in DHR and cytotoxicity was greater than that of anti-SRBC antibody
Incubation time Recovery ofRFC
T B
min % % %
Treated
0 1816
5 2218
15 24 t8
30 13 t 10
60 75115
120 80 f 13
180 95 t 18 63 32
Untreated
0 100 60 40
180 95 t 20 57 38
10 + 1210 90116 13018
20 + 37 112 95120 11512
40 + 35 t 14 99 t 15 130 t 18
40 - 95 t 10 95 t 10 100 t 20B. E. ELLIOTT, J . S. HASKILL, AND M. A. AXELRAD
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(Table II). Similarly, Cooper and Ada (1) reported high cross-reactivity between
different Salmonella flagellins of effector cells in DHR, but only slight cross-reac-
tivity of antisera directed against the same flagellin antigens. Similar cross-reac-
tivity, between DRBC and SRBC, of SRBC-immune cells in the production of
PFC was observed (Table II). However, cross-reactivity in the production of PFC
may represent a nonspecific stimulatory T-cell function (26) or a macrophage
function (27) . Since the degree of cross-reactivity is an indication of specificity,
these results suggest that the specificity of effector T cells in DHR is similar to
those in in vitro cytotoxicity; but both are different from that of B cells.
Although trypsinization inhibited the rosette-forming ability of immune
lymph node cells, these cells were capable of regenerating the ability to form
rosettes . The function of effector cells in in vitro cytotoxicity and DHR was
uninhibited (Tables III and IV). These results suggest that receptors for antigen
on medium lymphocyte effector cells are endogenous, although antibody from
contaminating B cells may have been passively absorbed .
The small lymphocyte required a longer period than the medium lymphocyte
to produce maximum swelling in vivo and detectable cytotoxicity in vitro (Fig.
7) . The small lymphocyte effector cell may transform into a medium lymphocyte
effector cell before producing its maximum effect. Such a transformation from
small to medium lymphocytes has been demonstrated in the graft-vs .-host
reaction in vivo (28) and in the development of hypersensitive lymphocytes in
vitro (29) .
However, small lymphocyte nonrosette-forming cells may become active
without transformation to medium lymphocytes. Evans et al . (30) have shown
that specific T cells activate macrophages with a specific macrophage-arming
factor in a syngeneic or allogeneic (tumor) immune system . Macrophages,
activated by small T lymphocytes, could conceivably be killer cells in the present
system . Mononuclear cells (of host origin [23]) which infiltrate into the skin
reactive site in vivo may become armed by the immune cells present and may
enhance the immune reaction against injected antigen. This would provide a
plausible explanation for the delayed effect shown with the nonrosette-forming
small T-lymphocyte population. Thus, although T cells are necessary for
cytotoxicity and DHR in the present system (Table I), cells other than T cells
may also be involved .
Sensitivity to anti-B serum, density, size, antigen-binding properties, and
kinetics failed to distinguish between effector cells in DHR and in vitro
cytotoxicity . The same effector cell may be detected in both assays. Factors
which produce positive skin reactions in DHA (31), may be secreted by the same
cell type that mediates cytotoxicity in vitro. DHR may therefore, be an in vivo
manifestation of the same type of cell-mediated immunity detected by in vitro
cytotoxicity .
Summary
Effector cells in delayed hypersensitivity and in vitrocytotoxicity were studied in
lymph node cells from animals immunized with sheep erythrocytes (SRBC) in
complete Freund's adjuvant. Delayed hypersensitivity response (DHR) was
assayed by the increase in foot pad swelling after the intrafoot pad iniection of598
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immune cells plus antigen. Cell-mediated cytotoxicity against SRBC was
assayed by a microcytotoxicity test with sheep fibroblasts as target cells. Effector
cells were antigen specific, sensitive to anti-9 serum plus complement (C), and
insensitive to anti-Ig serum plus C. A nonrosette-forming (non-RFC) small
lymphocyte effector T cell and a rosette-forming medium lymphocyte effector T
cell were isolated by velocity sedimentation . The small lymphocyte non-RFC
required a longer time than the medium lymphocyte RFC effector cell to produce
maximum activity. Buoyant density failed to distinguish medium lymphocyte
effector cells in DHR and in vitro cytotoxicity .
The authors wish to acknowledge the excellent technical assistance of Tyna Stokowski and Jana
Vesely.
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